Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620574 | 1.00 | BACE1 (0.55) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL5619596 | 0.85 | KLK5 (0.62) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL9394616 | 0.85 | KLK5 (0.62) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL7392856 | 0.83 | KLK5 (0.67) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL7398181 | 0.82 | BACE1 (0.65) | BACE1KLK5 | |
| SCHEMBL5395801 | 0.82 | KLK5 (0.58) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL5395803 | 0.82 | KLK5 (0.58) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL4043497 | 0.82 | REN (0.65) | REN | |
| SCHEMBL3361485 | 0.81 | KLK5 (0.63) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL6358023 | 0.81 | KLK5 (0.55) | KLK5APPPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-6992103-B2 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-31 | — | — | US | disclosed |
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-04-21 | — | — | US | disclosed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085520-A1 | Benzamide derivatives, processes for their preparation, and their pharmaceutical use | BACE2, PSEN2, BACE1 | BACE1 3/4885KLK5 3297/4885APP 5/4885 |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | BACE2, BACE1, PSEN2 | BACE1 2/4885KLK5 4341/4885APP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.